GlassScriptPhysician profile
Christopher Lee Shavers
NPI 1427295443
$5,846.26
in general payments reported to CMS, 2019-2025
47 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,348 · 2022: $1,062 · 2023: $1,170 · 2024: $979 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,309 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,308.52 |
| Education | $127.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $853.56 | 2021-2025 | |
| Janssen Biotech, INC. | $490.43 | 2021-2024 | Tremfya, Stelara, Simponi |
| Astrazeneca Pharmaceuticals LP | $462.70 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $446.54 | 2021-2025 | |
| Novo Nordisk INC | $431.59 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $410.53 | 2021-2025 | Mounjaro, Taltz, Olumiant |
| Amgen INC. | $354.39 | 2021-2025 | Enbrel, Tavneos, Repatha |
| Abbott Laboratories | $179.89 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $161.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.40 | 2022 | |
| Azurity Pharmaceuticals, INC. | $157.28 | 2023-2024 | Horizant, Edarbi, Horizant |
| Supernus Pharmaceuticals, INC. | $143.62 | 2022-2023 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $134.00 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.52 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $123.65 | 2021-2024 | Belsomra, Gardasil 9, Gardasil |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Shavers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.